Literature DB >> 8388519

Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans.

D C Ansardi1, D C Porter, C D Morrow.   

Abstract

Defective interfering (DI) RNA genomes of poliovirus which contain in-frame deletions in the P1 capsid protein-encoding region have been described. DI genomes are capable of replication and can be encapsidated by capsid proteins provided in trans from wild-type poliovirus. In this report, we demonstrate that a previously described poliovirus DI genome (K. Hagino-Yamagishi and A. Nomoto, J. Virol. 63:5386-5392, 1989) can be complemented by a recombinant vaccinia virus, VVP1 (D. C. Ansardi, D. C. Porter, and C. D. Morrow, J. Virol. 65:2088-2092, 1991), which expresses the poliovirus capsid precursor polyprotein, P1. Stocks of defective polioviruses were generated by transfecting in vitro-transcribed defective genome RNA derived from plasmid pSM1(T7)1 into HeLa cells infected with VVP1 and were maintained by serial passage in the presence of VVP1. Encapsidation of the defective poliovirus genome was demonstrated by characterizing poliovirus-specific protein expression in cells infected with preparations of defective poliovirus and by Northern (RNA) blot analysis of poliovirus-specific RNA incorporated into defective poliovirus particles. Cells infected with preparations of defective poliovirus expressed poliovirus protein 3CD but did not express capsid proteins derived from a full-length P1 precursor. Poliovirus-specific RNA encapsidated in viral particles generated in cells coinfected with VVP1 and defective poliovirus migrated slightly faster on formaldehyde-agarose gels than wild-type poliovirus RNA, demonstrating maintenance of the genomic deletion. By metabolic radiolabeling with [35S]methionine-cysteine, the defective poliovirus particles were shown to contain appropriate mature-virion proteins. This is the first report of the generation of a pure population of defective polioviruses free of contaminating wild-type poliovirus. We demonstrate the use of this recombinant vaccinia virus-defective poliovirus genome complementation system for studying the effects of a defined mutation in the P1 capsid precursor on virus assembly. Following removal of residual VVP1 from defective poliovirus preparations, processing and assembly of poliovirus capsid proteins derived from a nonmyristylated P1 precursor expressed by a recombinant vaccinia virus, VVP1 myr- (D. C. Ansardi, D. C. Porter, and C. D. Morrow, J. Virol. 66:4556-4563, 1992), in cells coinfected with defective poliovirus were analyzed. Capsid proteins generated from nonmyristylated P1 did not assemble detectable levels of mature virions but did assemble, at low levels, into empty capsids.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388519      PMCID: PMC237726     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  A Gly1 to Ala substitution in poliovirus capsid protein VP0 blocks its myristoylation and prevents viral assembly.

Authors:  D Marc; M Girard; S van der Werf
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

2.  Myristoylation is important at multiple stages in poliovirus assembly.

Authors:  N Moscufo; J Simons; M Chow
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

3.  Lack of myristoylation of poliovirus capsid polypeptide VP0 prevents the formation of virions or results in the assembly of noninfectious virus particles.

Authors:  D Marc; G Masson; M Girard; S van der Werf
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

4.  New evidence for the precursor role of 14 S subunits in poliovirus morphogenesis.

Authors:  B Rombaut; R Vrijsen; A Boeyé
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

5.  Myristoylation of the poliovirus polyprotein is required for proteolytic processing of the capsid and for viral infectivity.

Authors:  H G Kräusslich; C Hölscher; Q Reuer; J Harber; E Wimmer
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16.

Authors:  O Jenkins; J Cason; K L Burke; D Lunney; A Gillen; D Patel; D J McCance; J W Almond
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

7.  An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.

Authors:  D J Evans; J McKeating; J M Meredith; K L Burke; K Katrak; A John; M Ferguson; P D Minor; R A Weiss; J W Almond
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

8.  Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures.

Authors:  D C Ansardi; D C Porter; C D Morrow
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

9.  Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol, and env proteins from chimeric HIV-1-poliovirus minireplicons.

Authors:  W S Choi; R Pal-Ghosh; C D Morrow
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

10.  Role of myristoylation of poliovirus capsid protein VP4 as determined by site-directed mutagenesis of its N-terminal sequence.

Authors:  D Marc; G Drugeon; A L Haenni; M Girard; S van der Werf
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

View more
  15 in total

1.  Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity.

Authors:  Steffen Mueller; Dimitris Papamichail; J Robert Coleman; Steven Skiena; Eckard Wimmer
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  Oncolytic viral therapy of malignant glioma.

Authors:  Jacqueline Nuss Parker; David F Bauer; James J Cody; James M Markert
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  trans-encapsidation of a poliovirus replicon by different picornavirus capsid proteins.

Authors:  X Y Jia; M Van Eden; M G Busch; E Ehrenfeld; D F Summers
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  2A protease is not a prerequisite for poliovirus replication.

Authors:  Hiroko Igarashi; Yasuko Yoshino; Miwako Miyazawa; Hitoshi Horie; Seii Ohka; Akio Nomoto
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

5.  Encapsidation of the flavivirus kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans.

Authors:  A A Khromykh; A N Varnavski; E G Westaway
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag.

Authors:  D C Porter; L R Melsen; R W Compans; C D Morrow
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

7.  Poliovirus capsid proteins derived from P1 precursors with glutamine-valine cleavage sites have defects in assembly and RNA encapsidation.

Authors:  D C Ansardi; C D Morrow
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Functional coupling between replication and packaging of poliovirus replicon RNA.

Authors:  C I Nugent; K L Johnson; P Sarnow; K Kirkegaard
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Amino acid substitutions in the poliovirus maturation cleavage site affect assembly and result in accumulation of provirions.

Authors:  D C Ansardi; C D Morrow
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans.

Authors:  D C Porter; D C Ansardi; C D Morrow
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.